{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T03:35:34Z","timestamp":1773977734866,"version":"3.50.1"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["ECCS-1917166"],"award-info":[{"award-number":["ECCS-1917166"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000148","name":"National Science Foundation Division of Electrical Communications and Cyber Systems","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000148","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Computational Biology and Chemistry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.compbiolchem.2026.108898","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:13:00Z","timestamp":1768263180000},"page":"108898","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Boolean network-based identification of optimal drug combinations for prostate cancer"],"prefix":"10.1016","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5630-1916","authenticated-orcid":false,"given":"Pranabesh","family":"Bhattacharjee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Addanki Pratap","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aniruddha","family":"Datta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.compbiolchem.2026.108898_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12859-017-1522-2","article-title":"Towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer","volume":"18","author":"Arshad","year":"2017","journal-title":"BMC Bioinform."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib2","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib3","first-page":"494","article-title":"The role of androgen receptor in the progression of prostate cancer","volume":"52","author":"Byun","year":"2011","journal-title":"Korean J. Urol."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib4","first-page":"365","article-title":"Mechanisms of resistance in castration-resistant prostate cancer (CRPC)","volume":"4","author":"Chandrasekar","year":"2015","journal-title":"Transl. Androl. Urol."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib5","doi-asserted-by":"crossref","unstructured":"Chen, L., Wang, R.S., Zhang, X., 2009. Biomolecular Networks: Methods and Applications in Systems Biology. John Wiley & Sons. \u3008https:\/\/onlinelibrary.wiley.com\/doi\/book\/10.1002\/9780470488065\u3009, \u3008https:\/\/doi.org\/10.1002\/9780470488065\u3009.","DOI":"10.1002\/9780470488065"},{"key":"10.1016\/j.compbiolchem.2026.108898_bib6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib7","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0022-5347(05)64625-3","article-title":"A clinical study of 22.5 mg la-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer","volume":"168","author":"Chu","year":"2002","journal-title":"J. Urol."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217063","article-title":"Targeting (S6K\/NFk\u03b2\/SQSTM1\/Pol\u03b8 signaling to suppress radiation resistance in prostate cancer","volume":"597","author":"Clark","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib9","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s10555-013-9474-0","article-title":"Androgen receptor signaling in prostate cancer","volume":"33","author":"Culig","year":"2014","journal-title":"Cancer Metastas. Rev."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib10","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/JU.0000000000000117","article-title":"Targeting metastatic hormone sensitive prostate cancer: chemohormonal therapy and new combinatorial approaches","volume":"201","author":"Damodaran","year":"2019","journal-title":"J. Urol."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib11","unstructured":"Dana-Farber Cancer Institute, 2023. Protocol 23-235: a phase 1 study of the polymerase theta (pol) inhibitor novobiocin in brca-mutant and other dna damage repair-deficient solid tumors. \u3008https:\/\/www.dana-farber.org\/clinical-trials\/23-235\u3009. Clinical trial information including prostate cancer among solid tumor disease sites enrolled (ClinicalTrials.gov NCT05687110)."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib12","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3389\/fonc.2019.00858","article-title":"Androgen receptor signaling in the development of castration-resistant prostate cancer","volume":"9","author":"Feng","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib13","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.compbiolchem.2026.108898_bib14","unstructured":"of Genes, K.E., (KEGG), G., 2024. Pathway map hsa05215: prostate cancer. \u3008https:\/\/www.genome.jp\/pathway\/hsa05215\u3009. (Accessed 29 October 2024)."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.712505","article-title":"Navigating multi-scale cancer systems biology towards model-driven clinical oncology and its applications in personalized therapeutics","volume":"11","author":"Gondal","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib16","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","article-title":"Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non-castrate prostate cancer: Impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial","volume":"70","author":"Gravis","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1210\/edrv.23.2.0460","article-title":"Androgen receptor (AR) coregulators: an overview","volume":"23","author":"Heinlein","year":"2002","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib18","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.molonc.2011.07.001","article-title":"The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings","volume":"5","author":"Helleday","year":"2011","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib19","unstructured":"International Agency for Research on Cancer, 2024. Global cancer observatory: prostate cancer fact sheet. \u3008https:\/\/gco.iarc.who.int\/\u3009. Country-wise prostate cancer incidence for 2022 showing the United States with the highest incidence, followed by Brazil, Germany, and the United Kingdom."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib20","unstructured":"International Agency for Research on Cancer, 2024. Globocan 2022: prostate cancer fact sheet. \u3008https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/27-prostate-fact-sheet.pdf\u3009. 1,467,854 new cases of prostate cancer worldwide in 2022."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib21","article-title":"Berberine as a potential agent for the treatment of colorectal cancer","volume":"9","author":"Jiang","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib22","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1038\/onc.2013.206","article-title":"Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches","volume":"32","author":"Karantanos","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.compbiolchem.2026.108898_bib23","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.bmc.2013.12.056","article-title":"Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors","volume":"22","author":"Kusuma","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib24","doi-asserted-by":"crossref","DOI":"10.1109\/ACCESS.2023.3283291","article-title":"Drug target identification in triple negative breast cancer stem cell pathways: a computational study of gene regulatory pathways using boolean networks","author":"Lahiri","year":"2023","journal-title":"IEEE Access"},{"key":"10.1016\/j.compbiolchem.2026.108898_bib25","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.3892\/mmr.2014.3139","article-title":"Berberine inhibits the proliferation of prostate cancer cells and induces G0\/G1 or G2\/M phase arrest at different concentrations","volume":"11","author":"Lu","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib26","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.3389\/fonc.2019.01263","article-title":"A new era of prostate cancer precision medicine","volume":"9","author":"Malik","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib27","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1186\/s12935-021-02396-8","article-title":"p53 signaling in cancer progression and therapy","volume":"21","author":"Marei","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib28","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib29","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.18632\/aging.101250","volume":"9","author":"McCubrey","year":"2017","journal-title":"Aging"},{"key":"10.1016\/j.compbiolchem.2026.108898_bib30","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1177\/1756287215597633","article-title":"Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk","volume":"7","author":"Michaud","year":"2015","journal-title":"Ther. Adv. Urol."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib31","first-page":"190746","article-title":"A computational study of efficient combinations of FDA-approved drugs and dietary supplements in endometrial cancer","volume":"12","author":"Mondal","year":"2024","journal-title":"IEEE Access"},{"key":"10.1016\/j.compbiolchem.2026.108898_bib32","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/s41416-020-01105-y","article-title":"Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer","volume":"123","author":"Mout","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.compbiolchem.2026.108898_bib33","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.3892\/ijo.2016.3482","article-title":"Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells","volume":"48","author":"Ogura","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib34","series-title":"Global Cancer Burden Growing amidst Mounting Need for Services","author":"Organization","year":"2024"},{"key":"10.1016\/j.compbiolchem.2026.108898_bib35","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41571-018-0085-0","article-title":"Alternative splicing in prostate cancer","volume":"15","author":"Paschalis","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0093-7754(01)90148-4","article-title":"Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer","volume":"28","author":"Pienta","year":"2001","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib37","doi-asserted-by":"crossref","first-page":"11088","DOI":"10.3390\/ijms222011088","article-title":"Role of PI3K-AKT-mTOR pathway as a pro-survival signaling and resistance-mediating mechanism to therapy of prostate cancer","volume":"22","author":"Pungsrinont","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib38","article-title":"Prostate cancer: a review","author":"Raychaudhuri","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.compbiolchem.2026.108898_bib39","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/169170","article-title":"MAP kinases and prostate cancer","volume":"2012","author":"Rodr\u00edguez-Berriguete","year":"2012","journal-title":"J. Signal Transduct."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib40","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without prior chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib41","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1109\/TCBB.2020.3037318","article-title":"In silico modeling of the induction of apoptosis by cryptotanshinone in osteosarcoma cell lines","volume":"19","author":"Saraf","year":"2022","journal-title":"IEEE\/ACM Trans. Comput. Biol. Bioinform."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib42","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.3390\/ijms21124507","article-title":"The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling","volume":"21","author":"Shorning","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib43","unstructured":"American Cancer Society, 2026. Key statistics for prostate cancer. [online] Available at: https:\/\/www.cancer.org\/cancer\/types\/prostate-cancer\/about\/key-statistics.html (Accessed 15 January 2026)."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib44","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrclinonc.2014.163","article-title":"An update on PARP inhibitors-moving to the adjuvant setting","volume":"12","author":"Sonnenblick","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib45","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","article-title":"Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer","volume":"382","author":"Sternberg","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib46","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib47","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.maturitas.2015.01.015","article-title":"PARP inhibitors: a new era of targeted therapy","volume":"81","author":"Tangutoori","year":"2015","journal-title":"Maturitas"},{"key":"10.1016\/j.compbiolchem.2026.108898_bib48","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib49","first-page":"1413","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer","volume":"377","author":"Taplin","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib50","doi-asserted-by":"crossref","unstructured":"Valdespino-G\u00f3mez, V.M., et al., 2015. Interacci\u00f3n de las v\u00edas de se\u00f1alizaci\u00f3n intracelulares participantes en la proliferaci\u00f3n celular: potencial blanco de intervencionismo terap\u00e9utico [cell signaling pathways interaction in cellular proliferation: Potential target for therapeutic interventionism]. Cirug\u00eda y Cirujanos, vol. 83, pp. 165\u201374. \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/25986976\/\u3009, \u3008https:\/\/doi.org\/10.1016\/j.circir.2015.04.015\u3009.","DOI":"10.1016\/j.circir.2015.04.015"},{"key":"10.1016\/j.compbiolchem.2026.108898_bib51","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1109\/TCBB.2018.2872573","article-title":"In silico design and experimental validation of combination therapy for pancreatic cancer","volume":"17","author":"Vundavilli","year":"2020","journal-title":"IEEE\/ACM Trans. Comput. Biol. Bioinform."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib52","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/2580207","article-title":"Berberine modulates lpa function to inhibit the proliferation and inflammation of FLS-RA via p38\/ERK MAPK pathway mediated by LPA1","volume":"2019","author":"Wang","year":"2019","journal-title":"Evid.-Based Complement. Altern. Med."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib53","doi-asserted-by":"crossref","first-page":"6016","DOI":"10.1038\/s41467-022-33761-4","article-title":"Structural insight into the bulge-containing KRAS oncogene promoter G-quadruplex bound to berberine and coptisine","volume":"13","author":"Wang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib54","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1146\/annurev-pharmtox-052220-015912","article-title":"A new old target: androgen receptor signaling and advanced prostate cancer","volume":"62","author":"Westaby","year":"2022","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib55","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1042\/CS20160026","article-title":"Prostate cancer, PI3K, PTEN and prognosis","volume":"131","author":"Wise","year":"2017","journal-title":"Clin. Sci."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib56","unstructured":"World Cancer Research Fund International, 2022. Prostate cancer statistics. \u3008https:\/\/www.wcrf.org\/cancer-trends\/prostate-cancer-statistics\/\u3009. Reports high survival rates in developed countries and increased incidence among men aged over 65."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib57","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s43018-021-00203-x","article-title":"A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors","volume":"2","author":"Zhou","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.compbiolchem.2026.108898_bib58","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1093\/jsxmed\/qdad110","article-title":"Androgen receptors in sexual activity and their clinical implications","volume":"20","author":"Zitzmann","year":"2023","journal-title":"J. Sex. Med."},{"key":"10.1016\/j.compbiolchem.2026.108898_bib59","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/aps.2016.125","article-title":"Advances in the study of berberine and its derivatives: a focus on anti-tumor activity","volume":"38","author":"Zou","year":"2017","journal-title":"Acta Pharmacol. Sin."}],"container-title":["Computational Biology and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147692712600023X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147692712600023X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T02:42:00Z","timestamp":1773974520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147692712600023X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":59,"alternative-id":["S147692712600023X"],"URL":"https:\/\/doi.org\/10.1016\/j.compbiolchem.2026.108898","relation":{},"ISSN":["1476-9271"],"issn-type":[{"value":"1476-9271","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Boolean network-based identification of optimal drug combinations for prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Computational Biology and Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.compbiolchem.2026.108898","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108898"}}